Vertex Expands its 2018 Agreement with Arbor to Develop Novel Ex Vivo Engineered Cell Therapies
Shots:
- Arbor to receive an up front in cash & is eligible to receive an additional ~$1.2B on achievement of milestones across up to 7 programs along with royalties on sales on products emerges from the collaboration. Vertex will also invest in Arbor in the form of a convertible note
- Vertex get rights to use Arbor's technology to research & develop ex vivo engineered cell therapies for T1D- beta thalassaemia- sickle-cell disease- and other diseases
- The collaboration follows the 2018 agreement & will expands Vertex’s cell and gene therapies targeting multiple serious diseases. The agreement also determines the versatility and strength of Arbor’s platform
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com